Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplant

Abstract:

:On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel (KYMRIAH, Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor-T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). With this new era of personalized cancer immunotherapy, multiple challenges are present ranging from implementation of a CAR-T program to safe delivery of the drug, long-term toxicity monitoring and disease assessments. To address these issues, experts representing the American Society for Blood and Marrow Transplant (ASBMT), the European Group for Blood and Marrow Transplantation (EBMT), the International Society of Cell and Gene Therapy (ISCT), and the Foundation for the Accreditation of Cellular Therapy (FACT), formed a global CAR-T task force to identify and address key questions pertinent for hematologists and transplant physicians regarding the clinical use of anti CD19 CAR-T therapy in patients with B-ALL. This article presents an initial roadmap for navigating common clinical practice scenarios that will become more prevalent now that the first commercially available CAR-T product for B-ALL has been approved.

journal_name

Bone Marrow Transplant

authors

Kansagra AJ,Frey NV,Bar M,Laetsch TW,Carpenter PA,Savani BN,Heslop HE,Bollard CM,Komanduri KV,Gastineau DA,Chabannon C,Perales MA,Hudecek M,Aljurf M,Andritsos L,Barrett JA,Bachanova V,Bonini C,Ghobadi A,Gill SI,Hi

doi

10.1038/s41409-019-0451-2

subject

Has Abstract

pub_date

2019-11-01 00:00:00

pages

1868-1880

issue

11

eissn

0268-3369

issn

1476-5365

pii

10.1038/s41409-019-0451-2

journal_volume

54

pub_type

杂志文章
  • Cord blood stem cell transplantation for Diamond-Blackfan anemia.

    abstract::Bone marrow transplantation has been successfully employed in the treatment of Diamond-Blackfan anemia (DBA). Transplantation with bone marrow stem cells involves, however, considerable treatment-related toxicity, partially in the form of GVHD. Through the use of cord blood stem cells it may be possible to reduce the ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700675

    authors: Vettenranta K,Saarinen UM

    更新日期:1997-03-01 00:00:00

  • Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma.

    abstract::Still, many physicians give 4 cycles of combination therapy to multiple myeloma patients prior to collection of stem cells for autologous bone marrow transplant. This tradition originates from older doxorubicin-containing regiments which limited the number of cycles due to cumulative cardiotoxicity. Using older regime...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-018-0170-0

    authors: Tageja N,Korde N,Kazandjian D,Panch S,Manasanch E,Bhutani M,Kwok M,Mailankody S,Yuan C,Stetler-Stevenson M,Leitman SF,Sportes C,Landgren O

    更新日期:2018-11-01 00:00:00

  • Kaposi's sarcoma following allogeneic bone marrow transplantation.

    abstract::Localised Kaposi's sarcoma (KS) was diagnosed 240 days after allogeneic bone marrow transplantation (BMT) in a severely immunosuppressed HIV negative patient with genetic predisposition. The tumour was of host origin, based on PCR amplification of DNA minisatellites. Treatment with radiotherapy prompted almost complet...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Helg C,Adatto M,Salomon D,Roux E,Miralbell R,Chapuis B,Saurat JH

    更新日期:1994-12-01 00:00:00

  • Lymphocyte expansion after unrelated cord blood allogeneic stem cell transplantation in adults.

    abstract::Limited information is available regarding the incidence and features of lymphocyte expansions after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Large granular lymphocytes (LGL) expansions have been reported after bone marrow or peripheral blood, but not after unrelated cord blood (UCB) allo-HSCT, ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2016.364

    authors: Le Bris Y,Guillaume T,Ménard A,Illiaquer M,Martin J,Malard S,Duquesne A,Peterlin P,Debord C,Robillard N,Eveillard M,Wuillème S,Delaunay J,Mohty M,Garnier A,Moreau P,Béné MC,Chevallier P

    更新日期:2017-06-01 00:00:00

  • Autologous bone marrow transplantation for acute lymphoblastic leukemia.

    abstract::Between December 1979 and February 1991, 89 patients with ALL received autologous BMT. Median patient age was 18.4 years. Ten patients were in first remission, 52 were in second or greater remission and 27 were in relapse at the time of transplant. Conditioning regimens utilized chemotherapy alone (5 patients) or in c...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Doney K,Buckner CD,Fisher L,Petersen FB,Sanders J,Appelbaum FR,Anasetti C,Badger C,Bensinger W,Deeg HJ

    更新日期:1993-10-01 00:00:00

  • Use of cytosine arabinoside and total body irradiation as conditioning for allogeneic marrow transplantation in patients with acute lymphoblastic leukemia: a multicenter survey.

    abstract::We report the experience of 14 centers which have used the combination of cytosine arabinoside (ara-C; 24-36 g/m2) and total body irradiation (TBI) to prepare 213 patients with acute lymphoblastic leukemia (ALL) for allogeneic BMT. The overall 3-year disease-free survival (DFS) probability is 38% (95% CI: 31-45%); 75 ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Weyman C,Graham-Pole J,Emerson S,August C,Champlin R,Coccia P,Fay J,Harris R,Koch P,Johnson L

    更新日期:1993-01-01 00:00:00

  • Intravenous ribavirin therapy for adenovirus cystitis after allogeneic bone marrow transplantation.

    abstract::Acute hemorrhagic cystitis due to adenovirus infections may be more severe or protracted in immunocompromised patients. This patient with chronic graft-versus-host disease following allogeneic marrow transplantation for acute myelogenous leukemia developed painful hematuria due to adenovirus infection that failed to r...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Cassano WF

    更新日期:1991-03-01 00:00:00

  • Evaluation of uroprotective efficacy of amifostine against cyclophosphamide induced hemorrhagic cystitis.

    abstract::The role of amifostine in the prevention of cyclophosphamide-induced hemorrhagic cystitis (HC) was evaluated in the rat model. Urinary bladders from control rats that received no drugs (group I) were compared with those from rats receiving cyclophosphamide alone at a dose of 150 mg/kg (group II), and two other groups ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701598

    authors: Srivastava A,Nair SC,Srivastava VM,Balamurugan AN,Jeyaseelan L,Chandy M,Gunasekaran S

    更新日期:1999-03-01 00:00:00

  • CD3(+) and/or CD14(+) depletion from cord blood mononuclear cells before ex vivo expansion culture improves total nucleated cell and CD34(+) cell yields.

    abstract::Cord blood (CB) is used increasingly in transplant patients lacking sibling or unrelated donors. A major hurdle in the use of CB is its low cell dose, which is largely responsible for an elevated risk of graft failure and a significantly delayed neutrophil and platelet engraftment. As a positive correlation has been s...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2009.289

    authors: Yang H,Robinson SN,Lu J,Decker WK,Xing D,Steiner D,Parmar S,Shah N,Champlin RE,Munsell M,Leen A,Bollard C,Simmons PJ,Shpall EJ

    更新日期:2010-06-01 00:00:00

  • Allogeneic or haploidentical HSCT for refractory or relapsed solid tumors in children: toward a neuroblastoma model.

    abstract::New concepts of allogeneic hematopoietic SCT (allo-HSCT) for neuroblastoma and other solid tumors do not rely on escalation of chemotherapy intensity and tumor load reduction but rather on a graft-vs-tumor effect. At this point, this is still an investigational and unusual application of allogeneic transplant, with 78...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2008.279

    authors: Kanold J,Paillard C,Tchirkov A,Merlin E,Marabelle A,Lutz P,Rousseau R,Baldomero H,Deméocq F

    更新日期:2008-10-01 00:00:00

  • Expression of TNFalpha by CD3+ and F4/80+ cells following irradiation preconditioning and allogeneic spleen cell transplantation.

    abstract::The pathogenesis of acute graft-versus-host disease (aGVHD) includes tumor necrosis factor-alpha (TNFalpha) expression by macrophages and T cells. However, the temporal comparison of donor vs host cells to TNFalpha expression in response to irradiation conditioning and alloreactivity has not been reported. This study ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704362

    authors: Brown S,Konopa J,Zhou D,Thompson J

    更新日期:2004-02-01 00:00:00

  • Secondary solid tumors after allogeneic hematopoietic SCT in Japan.

    abstract::To evaluate the incidence and risk factors for secondary solid tumors in Japan after allogeneic hematopoietic SCT (allo-HSCT), 2062 patients who had received allo-HSCT between 1984 and 2005 were retrospectively analyzed. Twenty-eight patients who developed 30 solid tumors were identified a median of 5.6 years after tr...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/bmt.2011.23

    authors: Yokota A,Ozawa S,Masanori T,Akiyama H,Ohshima K,Kanda Y,Takahashi S,Mori T,Nakaseko C,Onoda M,Kishi K,Doki N,Aotsuka N,Kanamori H,Maruta A,Sakamaki H,Okamoto S,Kanto Study Group for Cell Therapy (KSGCT).

    更新日期:2012-01-01 00:00:00

  • Osteopetrosis: a single centre experience of stem cell tranisplantation and prenatal diagnosis.

    abstract::Malignant osteopetrosis (MOP) is an autosomal recessive disease in which osteoclast dysfunction results in excessive bone deposition and early infant death. Thirteen children suffering from MOP from four related families all belonging to one Bedouin tribe, were studied. The disease was diagnosed as early as at a few d...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702743

    authors: Kapelushnik J,Shalev C,Yaniv I,Aker M,Carmi R,Cohen Z,Mozer A,Schulman C,Stein G,Or R

    更新日期:2001-01-01 00:00:00

  • Does haploidentical transplantation in children with primary immunodeficiencies have the potential to exploit donor NK cell alloreactivity?

    abstract::Donor potential to exert NK cell alloreactivity has been shown to confer survival advantage in haploidentical hematopoietic cell transplantation for hematological malignancies. We investigated killer immunoglobulin receptor (KIR) ligand incompatibility in 40 children receiving haploidentical transplantation for primar...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704663

    authors: Dal-Cortivo L,Ouachée-Chardin M,Hirsch I,Blanche S,Fischer A,Cavazzana-Calvo M,Caillat-Zucman S

    更新日期:2004-12-01 00:00:00

  • Quality of life and psychological distress of bone marrow transplant recipients: the 'time trajectory' to recovery over the first year.

    abstract::The purpose of this study was to measure the trajectory of psychosocial recovery over the first year after bone marrow transplantation (BMT). BMT patients were assessed at baseline (n = 86), hospital discharge (n = 74), 100 days (n = 64) and at 1 year (n = 45). Participants completed the Functional Assessment of Cance...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1701115

    authors: McQuellon RP,Russell GB,Rambo TD,Craven BL,Radford J,Perry JJ,Cruz J,Hurd DD

    更新日期:1998-03-01 00:00:00

  • Donor lymphocyte infusion for treatment of life-threatening respiratory syncytial virus infection following bone marrow transplantation.

    abstract::We describe two patients who developed respiratory syncytial virus (RSV) pneumonia after BMT. One died of RSV pneumonia after three courses of steroid pulse therapy. Surprisingly, RSV antigen was identified in the bronchoalveolar lavage fluid (BALF) obtained post mortem. Steroid pulse therapy might have suppressed ant...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702559

    authors: Kishi Y,Kami M,Oki Y,Kazuyama Y,Kawabata M,Miyakoshi S,Morinaga S,Suzuki R,Mori S,Muto Y

    更新日期:2000-09-01 00:00:00

  • FK506-associated limbic injury following umbilical cord blood transplantation.

    abstract::A 5-year-old girl with Ph-positive chronic myelogenous leukemia, who underwent umbilical cord blood transplantation, developed two episodes of electrical status epilepticus while receiving tacrolimus (FK506) then cyclosporin A (CsA), as treatment against graft-versus-host disease. MRI including diffusion weighted MR i...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704168

    authors: Yoshida Y,Shimada H,Mori T,Yoshihara H,Takeoka M,Takahashi T

    更新日期:2003-09-01 00:00:00

  • Fludarabine induces growth arrest and apoptosis of cytokine- or alloantigen-stimulated peripheral blood mononuclear cells, and decreases production of Th1 cytokines via inhibition of nuclear factor kappaB.

    abstract::Fludarabine is a purine analog that has demonstrated significant activity in B-cell malignancies, including CLL. Fludarabine also possesses an immunosuppressive effect and is being used to prevent GVHD in hematopoietic stem cell transplantation. However, the molecular mechanism by which fludarabine inhibits immunoreac...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705901

    authors: Nishioka C,Ikezoe T,Togitani K,Yokoyama A

    更新日期:2008-02-01 00:00:00

  • Allogeneic stem cell transplantation for autoimmune diseases: nonmyeloablative conditioning regimens.

    abstract::Hematopoietic stem cell transplantation (HSCT) for autoimmune diseases have been, because of safety reasons, overwhelmingly autologous. Results are, in general, encouraging with improvement in quality of life, a remission of up to several years, and perhaps in some diseases improved survival. This indicates that furth...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1703950

    authors: Oyama Y,Traynor AE,Barr W,Burt RK

    更新日期:2003-08-01 00:00:00

  • Early cyclosporine taper in high-risk sibling allogeneic bone marrow transplants.

    abstract::Graft-versus-tumour reactions as a form of adoptive immunotherapy may help prevent the recurrence of haematological malignancy following allogeneic BMT. We hypothesised that such reactions may be maximised by shortening the duration of post-transplant immunosuppression by a rapid taper of cyclosporine (CYA). CYA dose ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1700961

    authors: Abraham R,Szer J,Bardy P,Grigg A

    更新日期:1997-11-01 00:00:00

  • Peripheral blood stem cell support does not accelerate haemopoietic recovery from miniBEAM chemotherapy.

    abstract::Intermediate-dose salvage therapy is frequently given for relapsed and resistant lymphomas and is usually intensely myelosuppressive. In an attempt to reduce the haematological toxicity of miniBEAM, one of the commonly used salvage regimens, peripheral blood stem cell (PBSC) support was given to 21 consecutive patient...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Fielding AK,Goldstone AH,Sullivan AM,Watts MJ,Jamieson E,Linch DC

    更新日期:1996-09-01 00:00:00

  • Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration.

    abstract::Relapse rates in patients after autologous bone marrow transplantation (BMT) for acute myeloid leukemia (AML) continue to be high despite the use of aggressive conditioning regimens. Based on studies in the murine system a clinical protocol was developed that utilizes immunotherapy to obtain a graft-versus-leukemia (G...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Klingemann HG,Eaves CJ,Barnett MJ,Eaves AC,Hogge DE,Nantel SH,Reece E,Shepherd JD,Sutherland HJ,Phillips GL

    更新日期:1994-09-01 00:00:00

  • Graft failure following neutrophil-specific alloantigen mismatched allogeneic BMT.

    abstract::We report a case of unexplained graft failure in a 33-year-old man who received an allogeneic bone marrow graft that contained a donor-recipient mismatch involving the highly immunogenic NA1 neutrophil-specific alloantigen system. Laboratory and clinical data suggest that an alloimmune process related to the neutrophi...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Klumpp TR,Herman JH,Mangan KF,Macdonald JS

    更新日期:1993-03-01 00:00:00

  • In utero transplantation of stem cells in humans: immunological aspects and clinical follow-up of patients.

    abstract::Four human fetuses were treated by transplantation of human fetal liver stem cells. Two of them had severe immunodeficiency disease and the two other ones had thalassemia major. Three of these in utero transplants were followed by engraftment. The three patients are now born: the first one is now very healthy thanks t...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Touraine JL,Raudrant D,Rebaud A,Roncarolo MG,Laplace S,Gebuhrer L,Betuel H,Frappaz D,Freycon F,Zabot MT

    更新日期:1992-01-01 00:00:00

  • FLAG chemotherapy followed by allogeneic stem cell transplant using nonmyeloablative conditioning induces regression of myelofibrosis with myeloid metaplasia.

    abstract::A 38-year-old woman with agnogenic myeloid metaplasia complicated by the poor prognostic factors of severe osteosclerosis, prominent hepatosplenomegaly, and profound anemia was treated with FLAG chemotherapy to decrease her organomegaly before undergoing a nonmyeloablative allogeneic stem cell transplant from a matche...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704172

    authors: Tanner ML,Hoh CK,Bashey A,Holman P,Sun C,Broome HE,Lane T,Ball ED,Carrier E

    更新日期:2003-09-01 00:00:00

  • Author Correction: High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II Study.

    abstract::In the original version of this article, the mention of 'ifosfamide 1500 mg/m2 days 1-3' should, in fact, read 'ifosfamide 1500 mg/m2 bd days 1-3'. This has now been updated in the original version of the article. ...

    journal_title:Bone marrow transplantation

    pub_type: 已发布勘误

    doi:10.1038/s41409-019-0504-6

    authors: Phillips EH,Lannon MM,Lopes A,Chadwick H,Jones G,Sieniawski M,Davies A,Wood K,Clifton-Hadley L,Smith P,Lawrie A,Chadwick N,Lennard AL

    更新日期:2020-04-01 00:00:00

  • High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem cell transplant recipients.

    abstract::In a series of 74 patients with hematological malignancies undergoing allogeneic bone marrow or peri- pheral blood stem cell transplants from an HLA-identical sibling donor, four developed diffuse alveolar hemorrhage (DAH) between days 0 and 23 post transplant. Diagnosis was made by the radiographic finding of diffuse...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701995

    authors: Raptis A,Mavroudis D,Suffredini A,Molldrem J,Rhee FV,Childs R,Phang S,Barrett A

    更新日期:1999-10-01 00:00:00

  • Role of allogenic bone marrow transplantation in adolescent or adult patients with acute lymphoblastic leukaemia or lymphoblastic lymphoma in first remission.

    abstract::Sixty-nine adolescents and adults 15-51 years of age with untreated acute lymphoblastic leukaemia (ALL, 54 patients) or lymphoblastic lymphoma (LL, 15 patients) were referred for intensive antileukaemic therapy. Patients were treated according to one of two protocols. Both included induction and consolidation with vin...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: De Witte T,Awwad B,Boezeman J,Schattenberg A,Muus P,Raemaekers J,Preijers F,Strijckmans P,Haanen C

    更新日期:1994-11-01 00:00:00

  • Outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome.

    abstract::HLA-identical sibling donor transplantation remains the treatment of choice for Wiskott-Aldrich Syndrome (WAS). Since 1990, utilization of alternative donor sources has increased significantly. We report the hematopoietic cell transplantation (HCT) outcomes of 47 patients with WAS treated at a single center since 1990...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2012.31

    authors: Shin CR,Kim MO,Li D,Bleesing JJ,Harris R,Mehta P,Jodele S,Jordan MB,Marsh RA,Davies SM,Filipovich AH

    更新日期:2012-11-01 00:00:00

  • Alternative donor transplant of benign primary hematologic disorders.

    abstract::Hematopoietic SCT is currently the only curative therapy for a range of benign inherited and acquired primary hematologic disorders in children, including BM failure syndromes and hemoglobinopathies. The preferred HLA-matched sibling donor is available for only about 25% of such children. However, there has been subst...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2015.1

    authors: Tolar J,Sodani P,Symons H

    更新日期:2015-05-01 00:00:00